PDSB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PDSB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the three months ended in Mar. 2024, PDS Biotechnology received $19.49 Mil more from issuing new shares than it paid to buy back shares. It spent $0.01 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.53 Mil on other financial activities. In all, PDS Biotechnology earned $20.01 Mil on financial activities for the three months ended in Mar. 2024.
The historical data trend for PDS Biotechnology's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PDS Biotechnology Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cash Flow from Financing | Get a 7-Day Free Trial | 0.75 | 29.83 | 48.89 | 34.29 | 16.38 |
PDS Biotechnology Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash Flow from Financing | Get a 7-Day Free Trial | 4.57 | 0.24 | 0.80 | 10.77 | 20.01 |
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
PDS Biotechnology's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Financing | (A: Dec. 2023 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 16.127 | + | 0 | + | -0.059 | + | 0 | + | 0 | + | 0.308 |
= | 16.38 |
PDS Biotechnology's Cash from Financing for the quarter that ended in Mar. 2024 is:
Cash Flow from Financing | (Q: Mar. 2024 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 19.494 | + | 0 | + | -0.013 | + | 0 | + | 0 | + | 0.531 |
= | 20.01 |
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $31.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PDS Biotechnology (NAS:PDSB) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
PDS Biotechnology's issuance of stock for the three months ended in Mar. 2024 was $19.49 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
PDS Biotechnology's repurchase of stock for the three months ended in Mar. 2024 was $0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
PDS Biotechnology's net issuance of debt for the three months ended in Mar. 2024 was $-0.01 Mil. PDS Biotechnology spent $0.01 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
PDS Biotechnology's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. PDS Biotechnology paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
PDS Biotechnology's cash flow for dividends for the three months ended in Mar. 2024 was $0.00 Mil. PDS Biotechnology received $0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
PDS Biotechnology's other financing for the three months ended in Mar. 2024 was $0.53 Mil. PDS Biotechnology received $0.53 Mil on other financial activities.
Thank you for viewing the detailed overview of PDS Biotechnology's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Spencer D. Brown | officer: Senior VP, General Counsel | 25B VREELAND ROAD, SUITE 300, FLORHAM PARK NJ 07932 |
Matthew C Hill | officer: Chief Financial Officer | C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044 |
Delyle W Bloomquist | director, 10 percent owner | RAYONIER ADVANCED MATERIALS INC., 1301 RIVERPLACE BLVD., SUITE 2300, JACKSONVILLE FL 32207 |
Voorhees Seth Van | officer: Chief Financial Officer | 12 HARVEY DRIVE, SHORT HILLS NJ 07078 |
Kamil Ali-jackson | director | C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355 |
Gregory Gene Freitag | director | 13631 PROGRESS BLVD., ALACHUA FL 32615 |
Stephen C. Glover | director | 108 DOCKSIDE CIRCLE, WESTON FL 33327 |
Otis W Brawley | director | 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518 |
Michael N. King | officer: Interim Chief Financial Office | 303A COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Ilian Iliev | director | 303 A COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Janetta Trochimiuk | officer: Principal Accounting Officer | 303A COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Richard Sykes | director | C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, FLORHAM PARK NJ 07932 |
Frank Bedu-addo | director, 10 percent owner, officer: President/CEO | 300 CONNELL DRIVE, SUITE 400, BERKELEY HEIGHTS NJ 07922 |
Lauren Wood | officer: Chief Medical Officer | 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922 |
Gregory Conn | officer: Chief Scientific Officer | 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922 |
From GuruFocus
By Marketwired • 07-11-2023
By sperokesalga sperokesalga • 06-05-2023
By Marketwired • 09-26-2023
By sperokesalga sperokesalga • 06-20-2023
By Marketwired • 09-20-2023
By sperokesalga sperokesalga • 05-25-2023
By Marketwired • 10-02-2023
By sperokesalga sperokesalga • 05-15-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.